Regeneron Pharmaceuticals Inc  

(Public, NASDAQ:REGN)   Watch this stock  
Find more results for REGN
302.16
-0.93 (-0.31%)
After Hours: 302.16 0.00 (0.00%)
Jul 28, 6:53PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 299.73 - 303.61
52 week 227.64 - 352.49
Open 302.25
Vol / Avg. 0.00/968,564.00
Mkt cap 30.48B
P/E 87.33
Div/yield     -
EPS 3.46
Shares 98.88M
Beta 0.98
Inst. own 75%
Aug 5, 2014
Q2 2014 Regeneron Pharmaceuticals Earnings Release - 9:30AM EDT - Add to calendar
Aug 5, 2014
Q2 2014 Regeneron Pharmaceuticals Inc Earnings Call - 8:30AM EDT - Add to calendar
Jun 13, 2014
Regeneron Pharmaceuticals Annual Shareholder Meeting
Jun 10, 2014
Regeneron Pharmaceuticals at Goldman Sachs Healthcare Conference
Jun 5, 2014
Regeneron Pharmaceuticals at Jefferies Global Healthcare Conference
May 28, 2014
Regeneron Pharmaceuticals at Sanford C Bernstein Strategic Decisions Conference
May 20, 2014
Regeneron Pharmaceuticals at UBS Global Healthcare Conference
May 14, 2014
Regeneron Pharmaceuticals at Bank of America Merrill Lynch Health Care Conference
May 12, 2014
Regeneron Pharmaceuticals at Citi Biotech Virtual Conference
May 8, 2014
Q1 2014 Regeneron Pharmaceuticals Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin 10.46% 20.16%
Operating margin 29.72% 36.11%
EBITD margin - 38.07%
Return on average assets 8.45% 16.87%
Return on average equity 12.61% 26.54%
Employees 2,340 -
CDP Score - -

Address

777 Old Saw Mill River Road
TARRYTOWN, NY 10591
United States - Map
+1-914-3477000 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Regeneron Pharmaceuticals, Inc. (Regeneron) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. As of December 31, 2011, the Company had two marketed products: EYLEA (aflibercept) Injection and ARCALYST (rilonacept) Injection for Subcutaneous Use. As of December 31, 2011, the Company had 13 product candidates in clinical development. Its Trap-based, late-stage programs are EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as vascular endothelial growth factor (VEGF) trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment.

Officers and directors

P. Roy Vagelos M.D. Chairman of the Board
Age: 84
Bio & Compensation  - Reuters
Leonard S. Schleifer M.D., Ph.D. President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Robert E. Landry Chief Financial Officer, Senior Vice President - Finance
Age: 50
Bio & Compensation  - Reuters
Joseph J. LaRosa Senior Vice President, General Counsel, Secretary
Age: 55
Bio & Compensation  - Reuters
Daniel P. Van Plew Senior Vice President, General Manager - Industrial Operations and Product Supply
Age: 41
Bio & Compensation  - Reuters
Murray A. Goldberg Senior Vice President - Administration, Assistant Secretary
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Peter Powchik M.D. Senior Vice President - Clinical Development
Age: 57
Bio & Compensation  - Reuters
Neil Stahl Ph.D. Senior Vice President - Research and Development Sciences
Age: 57
Bio & Compensation  - Reuters
Robert J. Terifay Senior Vice President - Commercial
Age: 54
Bio & Compensation  - Reuters
George D. Yancopoulos M.D., Ph.D. Chief Scientific Officer and President - Regeneron Laboratories, Director
Age: 54
Bio & Compensation  - Reuters